Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077792 · ClinicalTrials.gov registry record · Phase 3
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 20,506
- Enrollment target
NCT00077792 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 20,506 participants.
The verdict
NCT00077792, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20,506 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy
Interventions
- DRUG Enoxaparin sodium (XRP4563)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,506 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077792
The ClinicalTrials.gov registry entry for NCT00077792 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20,506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enoxaparin sodium (XRP4563) is the first listed.
NCT00077792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077792 about?
NCT00077792 is a clinical study titled "Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)". The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after randomization in patients with acute ST-segment elevation myocardial infarcti...
What is the current status of trial NCT00077792?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20,506 participants. The study started on 2002-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00077792?
The interventions under investigation include: Enoxaparin sodium (XRP4563) (DRUG).
Who is sponsoring clinical trial NCT00077792?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.